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ABSTRACT (241 words) 
 
Background: For the past decade 18F-Fluoro-ethyl-L-tyrosine (FET) and 18F-fluoro-deoxy-
glucose  (FDG) positron emitting tomography (PET) have been used for the assessment of 
patients with brain tumor. However, direct comparison studies only reported limited number 
of patients. Our purpose was to compare the diagnostic performance of FET and FDG-PET. 
Methods: We examined studies published between January 1995 and January 2015 in the 
PUBMED database. To be included the study should: 1) use FET and FDG-PET for the 
assessment of patients with isolated brain lesion 2) use histology as the gold standard. 
Analysis was performed on a per patient basis. Study quality was assessed with STARD and 
QUADAS criteria. 
Results: Five studies (119 patients) were included. For the diagnosis of brain tumor, FET-
PET demonstrated a pooled sensitivity of 0.94 (95% confidence interval [CI]: 0.79-0.98) and 
pooled specificity of 0.88 (95%CI:0.37-0.99), with an area under the curve (AUC) of 0.96 
(95%CI:0.94-0.97), a positive likelihood ratio (LR+) of 8.1 (95%CI:0.8-80.6) and negative 
likelihood ratio (LR–) of 0.07 (95%CI: 0.02-0.30) while FDG-PET demonstrated a sensitivity 
of 0.38 (95%CI:0.27-0.50) and specificity of 0.86 (95%CI:0.31-0.99), with an AUC of 0.40 
(95%CI:0.36-0.44), a LR+ of 2.7 (95%CI:0.3-27.8) and LR– of 0.72 (95%CI:0.47-1.11). 
Target-to-background ratios of either FDG or FET however allow distinction between low 
and high-grade gliomas (p>0.11). 
Conclusions: 
For brain tumor diagnosis, FET-PET performed much better than FDG and should be 
preferred when assessing a new isolated brain tumor. For glioma grading, both tracers 
however showed similar performances. 
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INTRODUCTION 
Primary brain tumors have an annual age-adjusted incidence rate of 28 per 100’000 in adults. 
Gliomas represent 28% of all tumors but 80% of malignant tumors 1. The World Health 
Organization (WHO) currently divides gliomas in four grades. Grade I and II tumors are 
considered as low-grade tumors that have a prolonged clinical course. Grade III (anaplastic 
glioma) or grade IV (glioblastoma) tumors are considered as high-grade lesions rapidely 
leading to death when left untreated 2. Adequate tumor diagnosis and grading is thus crucial to 
initiate proper treatment and improve patient’s outcome. 
Molecular imaging with positron-emission tomography (PET) helps to identify and 
delineate areas of tumor with increased growth activity 3. PET with 18F-fluoro-deoxy-glucose 
(FDG) was first used to detect and distinguish between low and high-grade tumors 4. 
However, FDG-PET is limited by high uptake in normal brain and unspecific uptake in 
inflammatory benign lesions 5. 18F-fluoro-ethyl-L-tyrosine (FET) is an artificial amino acid, 
which provides well-contrasted images in both high- and low-grade tumors while decreasing 
effective dose as compared to FDG 6. FET-PET demonstrated value for guiding biopsy 7,8, for 
diagnosing primary brain tumor 9,10, for directing radiotherapy 11 and for distinguishing 
between tumor recurrence and radionecrosis after initial therapy 12,13. Moreover, dynamic 
FET-PET analysis helps in differentiating low- from high-grade tumors 9,14,15 and in 
predicting patient’s outcome 16-18. 
Since FDG-PET is poorly reliable in predicting the neoplasic nature of a lesion due to 
uptake by inflammatory lesions, amino acid tracers such as FET have been developed in the 
past decades to increase specificity. However, to date, only a few studies limited to small 
patient populations directly compared FDG and FET diagnostic value.  
The purpose of this report is firstly to systematically review studies of the literature 
and perform a meta-analysis on diagnostic performance of FDG and FET-PET in patients 
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with brain tumors, and secondly to assess whether tracer uptake may allow distinction 
between non-tumor and tumor lesions. 
MATERIALS AND METHODS 
Data Sources and Search 
As the first reported study about FET synthesis was published in 1999 by Wester et al. 19, we 
performed a systematic search in the medical database PUBMED for English publications 
from January 1995 to January 2015 using the following search: “(“O-(2-fluoroethyl)tyrosine” 
[all fields] OR “(18F)fluoroethyltyrosine” [all fields] OR “Fluorodeoxyglucose F18” [Mesh]) 
AND (“PET” [all fields]) AND (“Glioma” [Mesh]) AND (“Humans” [Mesh])”. Errata, 
reviews, preclinical, animal, and nonradiopharmaceutical studies were excluded. 
 
Study Selection 
We considered studies using FET and FDG-PET for the assessment of patients with suspected 
brain tumors. Inclusion criteria were: 1) FET and FDG-PET used in the same patients with a 
newly diagnosed brain lesion or patients with suspicion of recurrence of a brain tumor; 2) 
patients who underwent or did not undergo radiotherapy, surgery, or chemotherapy before the 
PET studies; 3) use of histology as the gold standard to assess diagnostic performance. 
Studies in abstract form, case reports and studies including fewer than 10 patients were 
excluded.  
 
Data Extraction and Quality Assessment 
For each selected publication we extracted the following information: first author, year of 
publication, study population (number of patients who underwent FET and FDG for the 
assessment of brain tumor, sex, age, and histology), FET and FDG results (positive or 
negative, and target-to-background [TBR] ratio when reported). When possible, data were 
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recorded at the patient level. We used both checklists of the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS, scale 0–14) and Standards for Reporting Studies of Diagnostic 
Accuracy (STARD, scale 0–25) to assess study quality and applicability 20,21. 
 
Statistical Analysis 
All analyses were performed at the patient level with Stata 13.1 software (StataCorp LP, 
College Station, TX). A p-value less than 0.05 was considered statistically significant. 
Continuous variables are presented as mean± standard deviation (SD) or median (interquartile 
range [IQR]). Dichotomized histologic diagnosis (tumor or not, glioma or not) according to 
the classification of tumors of the central nervous system of the WHO 2 and the third edition 
of the International Classification of Diseases for Oncology (ICD-O-3) was used as the gold 
standard. Gliomas were defined by ICD-O-3 codes 9380-9384, 9391-9460, and 9480. Each 
study had its own criteria for defining FET and FDG-PET positivity. The bivariate mixed-
effects regression model was applied for data synthesis. Average sensitivity, specificity, 
positive and negative likelihood ratio (LR), diagnostic odds ratio (OR) and the respective 95% 
confidence intervals (95%CI) were calculated from the maximum likelihood estimates and 
graphically assessed by summarized receiver-operating-characteristic (SROC) curves. Forest 
plots, X2 test and Cochran Q were used to graphically and statistically assess heterogeneity of 
the results between studies. To statistically quantify inconsistency of the results between the 
studies we used the I2 statistic, which describes the percentage of total variation across studies 
attributable to heterogeneity rather than chance. The Funnel plot asymmetry test was used to 
assess publication bias. Finally after pooling all the patients, a ROC curve comparison 
between FDG and FET-PET performance for the diagnostic of either brain tumor versus non-
tumor lesions and brain glioma versus non-glioma lesions was performed. By convention, the 
small letter n and the capital letter N were used in the figures and text when describing the 
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number of studies (n) and the number of patients (N). 
Secondary analyses were performed at the patient level to compare quantitative FDG 
and FET uptake values. Patients were classified in three groups according to histological 
diagnosis (non-glioma tumor, glioma or non-tumor lesion). We then compared, among the 
groups, mean TBR (mean activity of the lesion divided by mean activity of the contralateral 
brain) or maximum TBR (maximum activity of the lesion divided by mean activity of the 
contralateral brain) measured on FDG and FET-PET images by Kruskall-Wallis test. We also 
compared mean TBR and maximum TBR values in glioma according to WHO grade to assess 
the ability of FDG and FET-PET to distinguish between low and high-grade gliomas. 
 
RESULTS 
Study Characteristics 
In total, 253 papers were identified in the PUBMED database. After exclusion of review 
articles (n [studies]= 16), case reports (n= 31), preclinical and animal studies (n= 25), errata 
and comments (n=5), 176 studies about the use of PET in humans with brain tumors were 
found. After applying the inclusion criteria, 3 studies remained, excluding reports using FDG-
PET alone (n=56), FET-PET alone (n=45) or other tracers alone or in combination with FDG-
PET (n=72). Two additional studies were found through reference screening of the papers 
(Figure 1). 
Overall, five studies including 190 patients (Table 1) respected the inclusion criteria 
and were included 22-26. In one study 26 all patients did not have both FDG and FET-PET for 
evaluation, only patients who underwent both imaging modalities (N=23) were thus included 
in the analysis. In one study 24, the histological diagnosis could not be established in three 
patients, and therefore only the remaining 18 patients were included in the analysis. Finally, 
in the study by Floeth et al. 22, we included 11 of 14 reported patients who had both FDG and 
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FET-PET examinations. Thus 119 patients remained (median age: 45[37-57] years, mean age: 
46±14 years, sex ratio: 2.2 M:F). Of these patients, 90 patients had a brain tumor, of whom 43 
had a low-grade glioma and 39 a high-grade glioma. Low-grade gliomas included pilocytic 
astrocytoma (N=1), ganglioglioma (N=1), astrocytomas (N=20), oligoastrocytomas (N=7), 
oligodendrogliomas (N=10) and four unspecified low-grade gliomas. High-grade gliomas 
included anaplastic astrocytomas (N=14), anaplastic oligoastrocytomas (N=5), anaplastic 
oligodendroglioma (N=1) and glioblastomas (N=19). Eight patients had a non-glioma brain 
tumor: metastasis (N=3), lymphoma (N=2), invasive adenoma (N=1), ganglioneuroblastoma 
(N=1) and meningioma (N=1). Twenty-nine patients had non-tumoral lesions including 9 
abscesses or empyemas, 4 hemorrhages, 2 encephalitis, 1 cortical dysplasia and 13 
unspecified lesions. 
 
Performances of FDG and FET-PET 
From the five selected studies, four with a total of 104 patients were used in the bivariate 
mixed-effects regression model. The fifth one 25 could not be included because it did not 
report any true-negative or false-positive case to compute specificity. However, the pooled 
results of the five studies (N=119 patients) were used to compare area under the curve of FDG 
and FET-PET. Criteria for FET and FDG-PET positivity varied between studies. Positivity 
definition was based on qualitative visual analysis as compared to non-tumor brain 
background in four studies 23-26 or on quantitative assessment of TBR using defined threshold 
in one study 22.  
 Including four of the five selected studies, FDG-PET demonstrated an overall 
sensitivity of 0.38 (95%CI: 0.27–0.50) and specificity of 0.86 (95%CI: 0.31–0.99), with an 
area under the curve of 0.40 (95%CI: 0.36–0.44), positive LR of 2.7 (95%CI: 0.3–27.8), 
negative LR of 0.72 (95%CI: 0.47–1.11) and diagnostic OR of 4 (95%CI: 0–58) for the 
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diagnosis of brain tumoral versus non-tumoral lesions. FET-PET demonstrated a sensitivity of 
0.94 (95%CI: 0.79–0.98) and specificity of 0.88 (95%CI: 0.37–0.99), with an area under the 
curve of 0.96 (95%CI: 0.94–0.97), positive LR of 8.1 (95%CI: 0.8–80.6), negative LR of 0.07 
(95%CI: 0.02–0.30) and diagnostic OR of 113 (95%CI: 4–2975).  
 For the diagnosis of glioma versus non-glioma lesions, FDG-PET demonstrated an 
overall sensitivity of 0.35 (95%CI: 0.11–0.71) and specificity of 0.65 (95%CI: 0.48–0.79), 
with an area under the curve of 0.60 (95%CI: 0.56–0.65), positive LR of 1.0 (95%CI: 0.4–2.7) 
negative LR of 1.0 (95%CI: 0.58–1.73) and diagnostic OR of 1.0 (95%CI: 0–5) whilst FET-
PET demonstrated an overall sensitivity of 0.92 (95%CI: 0.75–0.98) and specificity of 0.62 
(95%CI: 0.43–0.79), with an area under the curve of 0.89 (95%CI: 0.86–0.91), positive LR of 
2.4 (95%CI: 1.4–4.1), negative LR of 0.13 (95%CI: 0.04–0.48) and diagnostic OR of 18 
(95%CI: 4–92). 
 By pooling patients’ results of the five selected studies (N=119), FET-PET’s area 
under the curve (0.85 [95%CI: 0.77–0.93]) was significantly higher than FDG-PET’s area 
under the curve (0.56 [95%CI: 0.47–0.66], p<0.0001) for the diagnosis of brain tumor (Figure 
2). For the diagnosis of glioma, FET-PET’s area under the curve (0.76 [95%CI: 0.67–0.84]) 
was also significantly higher than FDG-PET’s area under the curve (0.49 [95%CI: 0.40–0.58], 
p<0.0001). 
 
Assessment of Heterogeneity, Inconsistency and Quality Studies 
For the differentiation between brain tumoral and non-tumoral lesions, a Forest plot did not 
show any significant performance heterogeneity (Cochran Q=3.4, p=0.092) but mild 
inconsistency between studies (I2 41% attributable to heterogeneity rather than chance) for 
FDG-PET. There was neither performance heterogeneity (Cochran Q=1.3, p=0.27) nor 
inconsistency (I2 0%) between studies for FET-PET. For the diagnosis of brain glioma versus 
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non-glioma lesions, a Forest plot showed major inconsistency between studies for FDG-PET 
(I2 100%) but not for FET-PET (I2 0%). This was mainly due to heterogeneity and 
inconsistency of sensitivity (Cochran Q=9.10, p=0.03 and I2 67%) due to the high sensitivity 
value of FDG-PET in the study by Floeth et al. 22 that includes only high grade gliomas with 
no false negative case (Figure 3). Funnel plots did not demonstrate publication bias for FDG 
(p>0.051) or FET (p>0.18) PET analysis. QUADAS and STARD scores for the assessment of 
study quality are reported in Figure 4. 
 
Quantitative analysis  
Among the five studies selected, only two (N=63) reported mean and maximum TBR values 
of the lesions for both FDG and FET-PET. Among these 63 cases, 47 gliomas, 2 non-glioma 
tumors and 14 non-tumoral lesions were included. Of the 47 gliomas, 22 were low-grade and 
25 high-grade lesions. Neither mean TBR (1.3±0.5 vs. 1.1±0.5, p=0.14) nor maximum TBR 
(2.0±1.0 vs. 1.8±0.9, p=0.32) on FDG-PET were significantly different between tumoral and 
non-tumoral lesions. On FET-PET images, both mean TBR (2.1±0.8 vs. 1.4±0.3, p=0.0015) 
and maximum TBR (2.9±1.2 vs. 1.9±0.5, p=0.0007) were significantly higher in tumoral than 
in non-tumoral lesions. 
 There was no statistically significant difference of mean TBR (2.1±0.9 vs. 2.0±0.1, p 
=0.69) and maximum TBR values (3.0±1.2 vs. 2.6±0.1, p=0.40) on FET-PET images between 
glial and non-glial tumors. FDG mean TBR (1.3±0.5 vs. 1.7±1.3, p=0.88) and maximum TBR 
values (2.0±0.9 vs. 2.5±1.9, p=0.88) were also not significantly different between glial and 
non-glial tumors.  
 Taking into account all gliomas (N=47), while mean TBR (2.1±0.9 vs. 1.4±0.3, p 
=0.003) and maximum TBR values (3.0±1.2 vs. 1.9±0.5, p=0.0009) on FET-PET images were 
significantly higher than in non-tumoral lesions, neither mean TBR (1.3±0.5 vs. 1.1±0.6, 
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p=0.15) nor maximum TBR values (2.0±0.9 vs. 1.8±0.9, p=0.33) on FDG-PET images were 
significantly different. However, both mean TBR and maximum TBR on FDG and FET-PET 
images were significantly higher in high-grade lesion (N=25) when compared to low-grade 
lesions (N=22) (Figure 5). ROC curve analysis showed that a mean TBR of at least 1.4 and a 
maximum TBR of at least 1.8 had the best value to distinguish between low and high-grade 
glioma with FDG-PET reaching a sensitivity, specificity and accuracy of 0.60, 0.91, 0.74 and 
0.72, 0.73, 0.72 respectively. For FET-PET we observed that a mean TBR of at least 2.0 and a 
maximum TBR of at least 3.0 reached a sensitivity, specificity and accuracy of 0.88, 0.73, 
0.81 and 0.80, 0.82, 0.81 respectively. Performances of these thresholds for glioma grading 
were not different between FDG and FET-PET using mean TBR (p=0.22) or maximum TBR 
(p=0.11). 
 
DISCUSSION 
The main results of this meta-analysis may be summarized as follows: (1) FET-PET 
demonstrated significantly higher diagnostic performance for the diagnosis of brain tumor 
(AUC of 0.96 vs. 0.40, p<0.0001) and glioma (AUC of 0.89 vs. 0.60, p<0.0001) as compared 
to FDG-PET; (2) Mean and maximum TBR values on FET-PET can distinguish between 
tumoral and non-tumoral lesions in the brain while mean and maximum TBR values on FDG-
PET cannot; and (3) Both FDG and FET quantitative parameters allow distinction between 
low and high-grade gliomas. 
Due to the known lack of specificity of conventional MRI to non-invasively 
characterize brain lesions, metabolic imaging using PET tracers has been increasingly studied. 
FDG-PET being limited by high uptake in normal brain and unspecific uptake in 
inflammatory benign lesions, radiolabeled amino acids tracers such as 11C-methionine (MET) 
and 18F-fluoro-ethyl-tyrosine have been developed to overcome these limitations. FET-PET 
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has demonstrated its value for the diagnosis 9,10 and grading 9,14,15 of newly identified brain 
tumor, for the diagnosis 27 and grading 28 of tumor recurrence, for the differentiation between 
brain tumor recurrence and radiation necrosis 12,13 and for the assessment of treatment 
response 29 with lower radiation burden than FDG-PET 6. However, only few studies with 
small patient populations report direct comparison of FET and FDG-PET for the qualitative 
and quantitative characterization of brain lesions in humans. In the presented meta-analysis, 
we demonstrated the strong advantage of FET-PET over FDG-PET for the diagnosis of brain 
tumors (AUC of 0.96 vs. 0.40, p<0.0001) and gliomas (AUC of 0.89 vs. 0.60, p<0.0001). 
This is in line with a recent meta-analysis reporting the good performance of FET-PET with 
an area under the curve of 0.84 (95%CI: 0.80-0.87) for the initial assessment of patients with 
new isolated brain lesions 9. Regarding clinical applications, due to positive and negative 
likelihood ratios of 2.7 (95%CI: 0.3-27.8) and 0.72 (95%CI: 0.47-1.11) respectively, FDG-
PET qualitative analysis has very small informational value for the differentiation of brain 
tumors versus non-tumoral lesions. In contrast, FET-PET positive and negative likelihood 
ratios (8.1 [95%CI: 0.8-80.6] and 0.07 [95%CI: 0.02-0.30], respectively) indicate that FET-
PET may help to exclude and to confirm the diagnosis of brain tumor. The higher accuracy 
for brain tumor diagnosis was also demonstrated with other radiolabeled amino acid tracers as 
compared to FDG-PET 30-33, especially in a recent meta-analysis by Zhao et al. 33 who argued 
for the excellent diagnostic performance of MET while conceding the major inconvenience of 
tracer supply. 
Regarding quantitative analysis, only mean and maximum TBR values on FET-PET 
images had the ability to distinguish between tumoral and non-tumoral brain lesions, mainly 
due to high FDG uptake in inflammatory lesions such as abscess, as previously 
demonstrated5. Based on the small number of cases where uptake quantification of the two 
tracers was performed, respective values for the differentiation of non-glioma versus glioma 
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tumors could not reliably be assessed in our study. However, both tracers were able to 
distinguish between low grade and high-grade gliomas, which is consistent with previously 
published studies on FET-PET 9,14,15,28,34 and FDG-PET 4,35-38. Though mean and maximum 
TBR cut-off values were different between FDG and FET-PET, performances were similar 
with both tracers (p>0.11) and close to those reported in the literature 4,14,15. Similar 
performance for distinguishing low and high-grade gliomas has also been reported for FDG-
PET and MET-PET 35,37. Among current amino acid tracers, the performance of FET-PET for 
glioma grading seems however to be better than 18F-fluoro-dihydroxy-phenalalanine 
(FDOPA) 39 and MET 40, the use of time-activity curve parameters from dynamic FET-PET 
acquisition 14,28,34,40 even improving tumor characterization. It is however important to take 
into account that glioma is a heterogeneous histological family. Oligodendroglial component 
may have a singular behavior both on FET-PET 41 and FDG-PET 35 that may impair 
diagnostic accuracy for both examination types. In a recent study, Manabe et al. 35 thus 
concluded that the results of PET imaging should be revised after obtaining histology report 
to better classify patient recurrence risk. 
Substantial data in the literature also demonstrated the value of FET-PET for guiding 
and evaluating response to therapy, and for the prediction of patient outcome. FET-PET may 
help to delineate tumoral volume before radiotherapy 11,42, to monitor the effects of 
radiotherapy 43,44 and chemotherapy 45,46. The prognostic value of FET-PET has also been 
demonstrated for the assessment of low-grade and high-grade gliomas. Floeth et al. 17 first 
found that low-grade gliomas exhibiting a diffuse tumoral pattern with positive uptake on 
baseline FET-PET have a significant lower progression-free survival. Two recent studies 
reported that dynamic FET-PET analysis could also help in identifying low-grade gliomas at 
high-risk of progression 47,48. FET-PET is also useful to evaluate patient prognosis in the 
preoperative, postoperative and pre-radiative phases of high-grade gliomas management 
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16,29,49-53. Untreated gliomas with high TBR on baseline static FET-PET images have a lower 
overall survival 49, while grade III astrocytoma tumors with an early minimal time-to-peak on 
dynamic FET-PET images exhibit similar survival than glioblastoma 50. Higher postoperative 
residual tumor volume on FET-PET and decreasing time-activity-curve 51,52 as well as 
decreasing time-activity-curve prior re-irradiation of recurrent glioblastoma 53 were also 
related to impaired patient survival. In contrast, early TBR decrease on serial static FET-PET 
examinations 16,29,54 but not dynamic FET-PET parameters changes 54 after 
radiochemotherapy in glioblastoma was associated with a better patient survival. Though the 
prognostic value of FDG-PET has also been reported in newly diagnosed and recurrent 
gliomas prior therapy 55-57 and for response assessment 58, it seems to be lower than for amino 
acid tracers PET 37,59. 
 Regarding the development of hybrid PET/MR imaging, it is furthermore worthy to 
mention that the respective value of combining FDG and FET-PET with MRI techniques 
cannot be deduced from this meta-analysis. FET-PET increases MRI accuracy 7,8 to guide 
biopsies, and notably helps in determining the outcome of patients with low-grade glioma 17. 
However, only few studies report combination of multiparametric MRI with quantitative 
analysis of FDG 38 or FET-PET 41,60,61. Yoon et al. 38 concluded that in case of concordant 
results of multiparametric MR techniques for high-grade lesions, the additive value of FDG 
PET may be limited. In contrast, combination of dynamic FET-PET with diffusion MRI 
improves glioma grading 41 and improves presurgical biopsy guidance 61 as compared to a 
single modality approach. Furthermore, spatial congruence of increased FET or FDOPA 
uptake area and abnormal area on enhanced MRI 62 or perfusion weighted MRI 60,63 are 
different, highlighting that practical guidelines for interpreting multimodal imaging have to be 
developed to ensure accurate glioma classification. The diagnostic superiority of combined 
FET-PET/MRI over FDG-PET/MRI in a same patient population also remains to be 
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demonstrated. Finally, although Heinzel et al. 64 demonstrated that the combined use of FET-
PET and conventional MRI was cost-effective in the planning of biopsies of glioma, the cost-
effectiveness of multiparametric MRI associated or not with FDG or FET-PET remains to be 
determined.  
Our systematic review of the literature only found five studies that directly compare 
FDG and FET-PET for assessing patients with suspected brain tumor. While all achieved a 
good quality (QUADAS scores >10 and STARD scores >18), the small number of studies 
resulted in substantial inconsistency between study results for FDG-PET but not for FET-
PET. No publication bias was observed for both tracers. There were however some 
limitations. First, only 4 studies were included in the meta-analysis because of the absence of 
true negative and false negative cases in one study. Second, due to the small number of 
pooled patients, a definitive conclusion about the value of FDG and FET TBR to differentiate 
gliomas (N= 47) versus non-glioma tumors (N= 2) cannot be reliably made. Though we did 
not observe patients characteristics overlap, the two studies that gave TBR values both on 
FDG and FET-PET came from the same institution, emphasizing the need of multicenter 
prospective studies to overcome limitations of single center multiple retrospective reports. 
Multicenter prospective studies could also assess the comparative value of parameters 
extracted from dynamic PET acquisition (i.e time-activity-curve for FET or cerebral 
metabolic rate of glucose for FDG) and from multiparametric MRI for the diagnostic and 
prognostic assessment of patients with brain tumors, which could not be performed hereby. 
On the basis of our systematic review and meta-analysis we could recommend that 
though FET-PET should be preferred to FDG-PET for the diagnosis of brain tumor and 
glioma. Moreover, FET and FDG TBR may be used indifferently to distinguish between low 
and high-grade gliomas. Multicentric multitracer studies should be developed to assess the 
respective values of dynamic PET parameters notably to distinguish between gliomas and 
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non-glioma tumors. Regarding the emergence of hybrid PET/MR imaging, development of 
integrated interpretation guidelines and evaluation of diagnostic performance and cost-
effectiveness of multiparametric MRI in comparison or in combination with PET is also 
mandatory in order to avoid wasting time and funds. 
 
CONCLUSION 
This systematic review and meta-analysis indicate that FET-PET has significant higher 
diagnostic performance for the diagnosis of brain tumor and glioma than FDG-PET. Although 
both FDG and FET quantitative parameters allow distinction between low and high-grade 
tumors, only TBR values on FET-PET can distinguish between tumoral and non-tumoral 
lesions, confirming FET-PET superiority over FDG-PET for brain lesion characterization. 
Additive value and cost-effectiveness of the use of FDG and FET-PET in combination with 
multiparametric MRI in the same population have to be assessed considering the development 
of hybrid PET/MR imaging and should provide new insights to reduce diagnostic time and 
cost.  
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Figure and captions 
Figure 1. Flowchart of study selection 
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Figure 2. Receiver Operating Characteristics curves for discrimination between brain tumoral 
and non-tumoral lesion for FDG-PET and FET-PET (N= 119 patients). Dashed line indicates 
FDG-PET; solid line indicates FET-PET; fine dashed line indicates chance. 
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Figure 3. Forest plot of studies included in the meta-analysis for discrimination between 
glioma versus non-glioma lesions with FDG-PET. 
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Figure 4. Study quality grading using QUADAS scores (range 0-14) and STARD scores 
(range 0-25). *Studies included in the meta-analysis. Dashed line indicates maximal score for 
QUADAS. 
* * * * * * *
0
5
10
15
20
25
QUADAS                                  STARD
1 2 3 4 5 1 2 3 4 5
*
 
N-O-D-15-00235R1 
	   27	  
Figure 5. TBR comparison according to histologic WHO grading. Light gray and medium 
light gray indicate mean TBR and maximum TBR from FDG-PET, medium dark and dark 
grey indicate mean TBR and maximum TBR from FET-PET. *p=0.0028 versus WHO grade 
I–II; **p=0.0065 versus WHO grade I–II, ||p=0.0001 versus WHO grade I–II. For comparison 
between non-tumoral lesions and WHO grade I–II gliomas, all p-values>0.44. 
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